The Therapeutic Effect of Modified Yu Ping Feng San on Idiopathic Sweating in End-Stage Cancer Patients during Hospice Care
The Therapeutic Effect of Modified Yu Ping Feng San on Idiopathic Sweating in End-Stage Cancer Patients during Hospice Care
复制标题
DOI：
10.1002/ptr.2633
复制
发表时间：
2009-03-01
影响因子：
7.2
通讯作者：
Chen, Yu-Jen
中科院分区：
文献类型：
--
作者：
Chiu, Shih-Che;Lai, Yuen-Liang;Chen, Yu-Jen
晚期癌症患者经常因不明原因的自发性出汗而僵硬。评价玉屏风散加减治疗特发性出汗的疗效（主要终点）和不良反应（次要终点）。32例接受临终关怀的终末期癌症患者入选，排除标准包括已知原因导致的出汗和服用可能影响出汗阈值的药物。用加味玉屏风散治疗10 d。出汗定量测定显示26例（81.3%）患者出汗完全缓解，平均减少50%所需时间为4.6天。患者和护理人员估计的视觉模拟量表（VAS）出汗评分显示，平均减少分别为8.4和9.1分。加味玉屏风散治疗后65.6%的患者食欲增加。最常见的治疗相关并发症为恶心（15.6%）、腹泻（9.3%）和过敏（3.1%），严重程度不超过2级，停止治疗后可逆。提示玉屏风散加味治疗晚期癌症不明原因特发性出汗安全有效。版权所有（C）2008约翰威利父子有限公司
End-stage cancer patients frequently stiffer from idiopathic sweating of unknown cause. This study was to evaluate the effect (primary endpoint) of modified Yu Ping Feng San on idiopathic sweating and adverse reactions (secondary endpoint). Thirty two end-stage cancer patients receiving hospice care, with exclusion criteria including sweating due to known causes and taking drugs which may affect the sweating threshold were enrolled. Patients received modified Yu Ping Feng San for 10 consecutive days. The quantitative measurement of sweating showed 26 patients (81.3%) had complete remission of sweating, and the average time required to reach 50% reduction was 4.6 days. The visual analog scale (VAS) sweating score estimated by patients and care-givers showed that the mean reductions were 8.4 and 9.1 points, respectively. An increase in appetite was experienced by 65.6% of patients, after administration of modified Yu Ping Feng San. The most prevalent treatment-related complications were nausea (15.6%), diarrhea (9.3%) and allergy (3.1%) without severity greater than grade 2, and these were reversible after cessation of treatment. These results suggest that modified Yu Ping Feng San is a safe and effective treatment for idiopathic sweating of unknown cause in end-stage cancer patients. Copyright (C) 2008 John Wiley & Sons, Ltd.